activity
20192022
most citedHigh-Throughput Virtual Screening of Small Molecule Inhibitors for SARS-CoV-2 Protein Targets with Deep Fusion Models

1 citations · 1 across the 3 of their papers we have counts for

collaborators

5 papers

cs.LG2022

Evaluating Point-Prediction Uncertainties in Neural Networks for Drug Discovery

Ya Ju Fan, Jonathan E. Allen, Kevin S. McLoughlin +4

Neural Network (NN) models provide potential to speed up the drug discovery process and reduce its failure rates. The success of NN models require uncertainty quantification (UQ) a…

cs.LG20211 cited

High-Throughput Virtual Screening of Small Molecule Inhibitors for SARS-CoV-2 Protein Targets with Deep Fusion Models

Garrett A. Stevenson, Derek Jones, Hyojin Kim +29

Structure-based Deep Fusion models were recently shown to outperform several physics- and machine learning-based protein-ligand binding affinity prediction methods. As part of a mu…

q-bio.QM2020

Machine Learning Models to Predict Inhibition of the Bile Salt Export Pump

Kevin S. McLoughlin, Claire G. Jeong, Thomas D. Sweitzer +7

Drug-induced liver injury (DILI) is the most common cause of acute liver failure and a frequent reason for withdrawal of candidate drugs during preclinical and clinical testing. An…

q-bio.BM2020

Split Optimization for Protein/Ligand Binding Models

Brian Davis, Kevin Mcloughlin, Jonathan Allen +1

In this paper, we investigate potential biases in datasets used to make drug binding predictions using machine learning. We investigate a recently published metric called the Asymm…

q-bio.QM2019

AMPL: A Data-Driven Modeling Pipeline for Drug Discovery

Amanda J. Minnich, Kevin McLoughlin, Margaret Tse +9

One of the key requirements for incorporating machine learning into the drug discovery process is complete reproducibility and traceability of the model building and evaluation pro…